MXPA01011834A - Derivados de purina, metodo de preparacion y composiciones farmaceuticas que los contienen. - Google Patents

Derivados de purina, metodo de preparacion y composiciones farmaceuticas que los contienen.

Info

Publication number
MXPA01011834A
MXPA01011834A MXPA01011834A MXPA01011834A MXPA01011834A MX PA01011834 A MXPA01011834 A MX PA01011834A MX PA01011834 A MXPA01011834 A MX PA01011834A MX PA01011834 A MXPA01011834 A MX PA01011834A MX PA01011834 A MXPA01011834 A MX PA01011834A
Authority
MX
Mexico
Prior art keywords
radical
formula
amino
cyclopentyl
alkyl
Prior art date
Application number
MXPA01011834A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Luc Haesslein
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of MXPA01011834A publication Critical patent/MXPA01011834A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA01011834A 1999-05-21 2000-05-18 Derivados de purina, metodo de preparacion y composiciones farmaceuticas que los contienen. MXPA01011834A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9906456A FR2793794B1 (fr) 1999-05-21 1999-05-21 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
PCT/FR2000/001335 WO2000071543A1 (fr) 1999-05-21 2000-05-18 Derives de la purine, leur procede de preparation, et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
MXPA01011834A true MXPA01011834A (es) 2002-04-17

Family

ID=9545846

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01011834A MXPA01011834A (es) 1999-05-21 2000-05-18 Derivados de purina, metodo de preparacion y composiciones farmaceuticas que los contienen.

Country Status (33)

Country Link
US (2) US7122669B1 (enExample)
EP (1) EP1183256B1 (enExample)
JP (1) JP2003500407A (enExample)
KR (1) KR100707895B1 (enExample)
CN (1) CN1298719C (enExample)
AP (1) AP1477A (enExample)
AR (1) AR035317A1 (enExample)
AT (1) ATE370951T1 (enExample)
AU (1) AU4764500A (enExample)
BR (1) BR0011282A (enExample)
CA (1) CA2374714A1 (enExample)
CZ (1) CZ20014163A3 (enExample)
DE (1) DE60036102T2 (enExample)
DK (1) DK1183256T3 (enExample)
DZ (1) DZ3166A1 (enExample)
EA (1) EA005072B1 (enExample)
ES (1) ES2290033T3 (enExample)
FR (1) FR2793794B1 (enExample)
HU (1) HUP0201649A3 (enExample)
IL (1) IL146441A0 (enExample)
MA (1) MA26791A1 (enExample)
MX (1) MXPA01011834A (enExample)
NO (1) NO20015659L (enExample)
NZ (1) NZ515556A (enExample)
PL (1) PL352293A1 (enExample)
PT (1) PT1183256E (enExample)
SK (1) SK16722001A3 (enExample)
TR (1) TR200103349T2 (enExample)
TW (1) TWI284130B (enExample)
UA (1) UA68441C2 (enExample)
WO (1) WO2000071543A1 (enExample)
YU (1) YU86601A (enExample)
ZA (1) ZA200109602B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
EP1377579B1 (en) * 2000-10-31 2009-03-25 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6861524B2 (en) * 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
AU2003301407B2 (en) * 2002-10-15 2010-04-22 Irm Llc Compositions and methods for inducing osteogenesis
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
WO2005047524A2 (en) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP4086257A1 (en) * 2016-09-30 2022-11-09 SRI International Dual clk/cdk1 inhibitors for cancer treatment
CZ308029B6 (cs) 2017-03-20 2019-11-06 Univerzita PalackĂ©ho v Olomouci 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky
AR131380A1 (es) 2022-12-16 2025-03-12 Astrazeneca Ab Purinas 2,6,9-trisustituidas

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
EP0841810B1 (en) * 1991-12-05 2000-06-21 Texas Instruments Incorporated Method to improve a video signal
CA2084222C (en) * 1991-12-06 2004-04-06 David R. Borcherding Novel trans cyclopentanyl purine analogs useful as immunosuppressants
CN1066147C (zh) * 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Also Published As

Publication number Publication date
EA200101224A1 (ru) 2002-10-31
NZ515556A (en) 2003-08-29
HUP0201649A3 (en) 2003-01-28
US7208598B2 (en) 2007-04-24
UA68441C2 (en) 2004-08-16
EA005072B1 (ru) 2004-10-28
YU86601A (sh) 2005-07-19
ATE370951T1 (de) 2007-09-15
TR200103349T2 (tr) 2002-05-21
EP1183256A1 (fr) 2002-03-06
DE60036102T2 (de) 2008-05-15
JP2003500407A (ja) 2003-01-07
ES2290033T3 (es) 2008-02-16
IL146441A0 (en) 2002-07-25
TWI284130B (en) 2007-07-21
DE60036102D1 (de) 2007-10-04
US20050187228A1 (en) 2005-08-25
BR0011282A (pt) 2002-02-26
AP2001002355A0 (en) 2001-12-31
CN1298719C (zh) 2007-02-07
NO20015659D0 (no) 2001-11-20
PL352293A1 (en) 2003-08-11
ZA200109602B (en) 2003-01-29
NO20015659L (no) 2002-01-18
AP1477A (en) 2005-10-19
US7122669B1 (en) 2006-10-17
CA2374714A1 (fr) 2000-11-30
WO2000071543A1 (fr) 2000-11-30
FR2793794A1 (fr) 2000-11-24
HUP0201649A2 (en) 2002-08-28
MA26791A1 (fr) 2004-12-20
CZ20014163A3 (cs) 2002-10-16
KR20010113975A (ko) 2001-12-28
AU4764500A (en) 2000-12-12
KR100707895B1 (ko) 2007-04-17
PT1183256E (pt) 2007-11-13
CN1361780A (zh) 2002-07-31
DK1183256T3 (da) 2007-12-03
EP1183256B1 (fr) 2007-08-22
SK16722001A3 (sk) 2003-01-09
AR035317A1 (es) 2004-05-12
DZ3166A1 (fr) 2000-11-30
FR2793794B1 (fr) 2001-07-27

Similar Documents

Publication Publication Date Title
US7122669B1 (en) Purine derivatives, preparation method and pharmaceutical compositions containing same
EP3565815B1 (en) Compounds as bcl-2-selective apoptosis-inducing agents
US20040053925A1 (en) Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use
CN101137363A (zh) 作为甘氨酸转运体1(GlyT-1)抑制剂用于治疗神经学和神经精神病学障碍的[4-(杂芳基)哌嗪-1-基]-(2,5-取代的-苯基)甲酮衍生物
HUP0402504A2 (hu) Purinszármazékok, mint purinerg receptor antagonisták
WO1996018607A1 (en) Aniline derivative having the effect of inhibiting nitrogen monoxide synthase
JP5669926B2 (ja) プリン化合物
CA3036382A1 (en) Diaryl purine derivatives with improved bioavailability
CN106748892B (zh) 靶向自噬激动剂及其在神经退行性疾病治疗药物中的应用
JP4157158B2 (ja) ドーパミン作動薬の新規な塩の形態
CN105153163A (zh) 2,9-二取代嘌呤-6-氨基异羟肟酸类组蛋白去乙酰化酶抑制剂及制备方法和应用
AU2006202270A1 (en) Purine derivatives, preparation method and pharmaceutical compositions containing same
FR2877667A1 (fr) Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
ES2965684T3 (es) Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
CN103122003A (zh) 具有抗肿瘤活性的萘醌类化合物
JP2018537530A (ja) 滑膜肉腫を処置するための化合物および方法
WO2008088927A1 (en) Pharmaceuticals, compositions and methods of making and using the same
JPS63183557A (ja) 放射線療法の補助剤として有用な2−(置換スルフアミル)−6−ニトロ安息香酸類誘導体
HK1116486A (en) Novel salt form of a dopamine agonist
CN103122004A (zh) 具有抗肿瘤活性的萘醌类化合物

Legal Events

Date Code Title Description
FG Grant or registration